Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel.

Our research provides a detailed map of alterations in response to cisplatin and paclitaxel treatment, provides crucial insights into the molecular basis of their action, and paves the way for further research to identify molecular targets for this elusive malignancy.